Pipeline

Pipeline


Product / Indication Pre Clinical Phase 1 Phase 2 Phase 3 NDA Approved
Commercialized
TAVALISSE®*
Indication: Immune Thrombocytopenia
Target: SYK
  • 100%
Clinical Trials¹
TAVALISSE (Fostamatinib)
Indication: Warm AIHA
Target: SYK
  • 61%
R835
Indication: Immune Disease
Target: IRAK
  • 38%
BGB324 - BerGenBio
Indication: Cancer
Target: AXL
  • 50%
ATI-501 & 502 - Aclaris
Indication: Dermatology
Target: JAK
  • 50%
DS-3032 - Daiichi Sankyo
Indication: Cancer
Target: MDM2
  • 39%
AZD0449 - AstraZeneca
Indication: Chronic Asthma
Target: JAK
  • 25%
Partner-sponsored Trials
Company-sponsored Trials



*Please see the TAVALISSE full Prescribing Information at www.TAVALISSE.com
¹Investigational compounds in these indications have not been submitted for FDA review